Gregory M. Bokar
Directeur/Bestuurslid bij Sunovion CNS Development Canada Ulc
Profiel
Gregory M.
Bokar is currently working as Secretary & Director at Sunovion Pharmaceuticals Europe Ltd.
and as Director at Sunovion CNS Development Canada Ulc.
He previously worked as Director at Cynapsus Therapeutics, Inc.
Actieve functies van Gregory M. Bokar
Bedrijven | Functie | Begin |
---|---|---|
Sunovion CNS Development Canada Ulc
Sunovion CNS Development Canada Ulc Pharmaceuticals: MajorHealth Technology Sunovion CNS Development Canada Ulc develops pharmaceuticals products. The company is headquartered in Vancouver, Canada. | Directeur/Bestuurslid | 21-10-2016 |
Sunovion Pharmaceuticals Europe Ltd.
Sunovion Pharmaceuticals Europe Ltd. Pharmaceuticals: MajorHealth Technology Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals. | Directeur/Bestuurslid | 15-07-2019 |
Eerdere bekende functies van Gregory M. Bokar
Bedrijven | Functie | Einde |
---|---|---|
CYNAPSUS THERAPEUTICS INC | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Cynapsus Therapeutics, Inc.
Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada. | Health Technology |
Sunovion CNS Development Canada Ulc
Sunovion CNS Development Canada Ulc Pharmaceuticals: MajorHealth Technology Sunovion CNS Development Canada Ulc develops pharmaceuticals products. The company is headquartered in Vancouver, Canada. | Health Technology |
Sunovion Pharmaceuticals Europe Ltd.
Sunovion Pharmaceuticals Europe Ltd. Pharmaceuticals: MajorHealth Technology Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals. | Health Technology |